ID   DAPK3_HUMAN             Reviewed;         454 AA.
AC   O43293; A0AVN4; B3KQE2; Q05JY4;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Death-associated protein kinase 3;
DE            Short=DAP kinase 3;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528, ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835};
DE   AltName: Full=DAP-like kinase;
DE            Short=Dlk;
DE   AltName: Full=MYPT1 kinase;
DE   AltName: Full=Zipper-interacting protein kinase;
DE            Short=ZIP-kinase;
GN   Name=DAPK3; Synonyms=ZIPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9488481; DOI=10.1128/MCB.18.3.1642;
RA   Kawai T., Matsumoto M., Takeda K., Sanjo H., Akira S.;
RT   "ZIP kinase, a novel serine/threonine kinase which mediates
RT   apoptosis.";
RL   Mol. Cell. Biol. 18:1642-1651(1998).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND
RP   COFACTOR.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10356987; DOI=10.1016/S0014-5793(99)00550-5;
RA   Murata-Hori M., Suizu F., Iwasaki T., Kikuchi A., Hosoya H.;
RT   "ZIP kinase identified as a novel myosin regulatory light chain kinase
RT   in HeLa cells.";
RL   FEBS Lett. 451:81-84(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 165-454 (ISOFORM 2), ALTERNATIVE
RP   SPLICING, FUNCTION IN PHOSPHORYLATION OF MYOSIN; PPP1R12A AND MYL12B,
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL
RP   PROPERTIES, INTERACTION WITH PPP1R12A AND MYOSIN, AUTOPHOSPHORYLATION,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Urinary bladder;
RX   PubMed=17126281; DOI=10.1016/j.abb.2006.09.026;
RA   Takamoto N., Komatsu S., Komaba S., Niiro N., Ikebe M.;
RT   "Novel ZIP kinase isoform lacks leucine zipper.";
RL   Arch. Biochem. Biophys. 456:194-203(2006).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF MUSCLE MYL12B, AND CATALYTIC ACTIVITY.
RX   PubMed=11384979; DOI=10.1074/jbc.M102753200;
RA   Niiro N., Ikebe M.;
RT   "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle
RT   contraction via myosin light chain phosphorylation.";
RL   J. Biol. Chem. 276:29567-29574(2001).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF NON-MUSCLE MYL12B, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=11781833; DOI=10.1038/sj.onc.1205055;
RA   Murata-Hori M., Fukuta Y., Ueda K., Iwasaki T., Hosoya H.;
RT   "HeLa ZIP kinase induces diphosphorylation of myosin II regulatory
RT   light chain and reorganization of actin filaments in nonmuscle
RT   cells.";
RL   Oncogene 20:8175-8183(2001).
RN   [8] {ECO:0000305}
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH DAXX AND PAWR.
RX   PubMed=12917339; DOI=10.1128/MCB.23.17.6174-6186.2003;
RA   Kawai T., Akira S., Reed J.C.;
RT   "ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.";
RL   Mol. Cell. Biol. 23:6174-6186(2003).
RN   [9]
RP   INTERACTION WITH PPP1R12A, AND TISSUE SPECIFICITY.
RX   PubMed=15292222; DOI=10.1074/jbc.M403676200;
RA   Endo A., Surks H.K., Mochizuki S., Mochizuki N., Mendelsohn M.E.;
RT   "Identification and characterization of zipper-interacting protein
RT   kinase as the unique vascular smooth muscle myosin phosphatase-
RT   associated kinase.";
RL   J. Biol. Chem. 279:42055-42061(2004).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF MYL12B, AND CATALYTIC ACTIVITY.
RX   PubMed=15096528; DOI=10.1083/jcb.200309056;
RA   Komatsu S., Ikebe M.;
RT   "ZIP kinase is responsible for the phosphorylation of myosin II and
RT   necessary for cell motility in mammalian fibroblasts.";
RL   J. Cell Biol. 165:243-254(2004).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT THR-299; SER-309; SER-311; SER-312;
RP   SER-318 AND SER-326, PHOSPHORYLATION BY DAPK1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15367680; DOI=10.1128/MCB.24.19.8611-8626.2004;
RA   Shani G., Marash L., Gozuacik D., Bialik S., Teitelbaum L., Shohat G.,
RA   Kimchi A.;
RT   "Death-associated protein kinase phosphorylates ZIP kinase, forming a
RT   unique kinase hierarchy to activate its cell death functions.";
RL   Mol. Cell. Biol. 24:8611-8626(2004).
RN   [12]
RP   INTERACTION WITH STAT3.
RX   PubMed=16219639; DOI=10.1093/intimm/dxh331;
RA   Sato N., Kawai T., Sugiyama K., Muromoto R., Imoto S., Sekine Y.,
RA   Ishida M., Akira S., Matsuda T.;
RT   "Physical and functional interactions between STAT3 and ZIP kinase.";
RL   Int. Immunol. 17:1543-1552(2005).
RN   [13]
RP   INTERACTION WITH TCP10L, AND SUBCELLULAR LOCATION.
RX   PubMed=15910542; DOI=10.1111/j.1365-2605.2005.00522.x;
RA   Yu H., Jiang D., Guo Z., Saiyin H., Guo J., Wang X., Yu L.;
RT   "TCP10L is expressed specifically in spermatogenic cells and binds to
RT   death associated protein kinase-3.";
RL   Int. J. Androl. 28:163-170(2005).
RN   [14]
RP   PHOSPHORYLATION AT THR-180; THR-225; THR-265; THR-299; THR-306 AND
RP   SER-311, ENZYME REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   THR-299; 299-THR-THR-300; VAL-427; VAL-434 AND LEU-441.
RX   PubMed=15611134; DOI=10.1074/jbc.M412538200;
RA   Graves P.R., Winkfield K.M., Haystead T.A.;
RT   "Regulation of zipper-interacting protein kinase activity in vitro and
RT   in vivo by multisite phosphorylation.";
RL   J. Biol. Chem. 280:9363-9374(2005).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and
RT   beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [16]
RP   FUNCTION, ENZYME REGULATION, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT
RP   THR-180; THR-265 AND THR-299, AND MUTAGENESIS OF LYS-42; ASP-161;
RP   THR-225; THR-265 AND THR-299.
RX   PubMed=17158456; DOI=10.1074/jbc.M609990200;
RA   Hagerty L., Weitzel D.H., Chambers J., Fortner C.N., Brush M.H.,
RA   Loiselle D., Hosoya H., Haystead T.A.;
RT   "ROCK1 phosphorylates and activates zipper-interacting protein
RT   kinase.";
RL   J. Biol. Chem. 282:4884-4893(2007).
RN   [17]
RP   SUBCELLULAR LOCATION, AND ABSENCE OF INTERACTION WITH PARW.
RX   PubMed=17953487; DOI=10.1371/journal.pgen.0030180;
RA   Shoval Y., Pietrokovski S., Kimchi A.;
RT   "ZIPK: a unique case of murine-specific divergence of a conserved
RT   vertebrate gene.";
RL   PLoS Genet. 3:1884-1893(2007).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   DOI=10.1002/sita.200600112;
RA   Scheidtmann K.H.;
RT   "Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple
RT   functions.";
RL   Signal Transduct. 7:248-259(2007).
RN   [19]
RP   FUNCTION IN PHOSPHPRYLATION OF RPL13A, AND CATALYTIC ACTIVITY.
RX   PubMed=18995835; DOI=10.1016/j.molcel.2008.09.019;
RA   Mukhopadhyay R., Ray P.S., Arif A., Brady A.K., Kinter M., Fox P.L.;
RT   "DAPK-ZIPK-L13a axis constitutes a negative-feedback module regulating
RT   inflammatory gene expression.";
RL   Mol. Cell 32:371-382(2008).
RN   [20]
RP   FUNCTION IN ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTION.
RX   PubMed=18084323; DOI=10.1038/sj.onc.1210995;
RA   Leister P., Felten A., Chasan A.I., Scheidtmann K.H.;
RT   "ZIP kinase plays a crucial role in androgen receptor-mediated
RT   transcription.";
RL   Oncogene 27:3292-3300(2008).
RN   [21]
RP   FUNCTION AS TUMOR SUPPRESSOR, CHARACTERIZATION OF VARIANTS MET-112;
RP   ASN-161 AND SER-216, MUTAGENESIS OF THR-180, AND SELF-ASSOCIATION.
RX   PubMed=21487036; DOI=10.1158/0008-5472.CAN-10-3543;
RA   Brognard J., Zhang Y.W., Puto L.A., Hunter T.;
RT   "Cancer-associated loss-of-function mutations implicate DAPK3 as a
RT   tumor-suppressing kinase.";
RL   Cancer Res. 71:3152-3161(2011).
RN   [22]
RP   PHOSPHORYLATION AT THR-299, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   294-ARG-ARG-295.
RX   PubMed=20854903; DOI=10.1016/j.cellsig.2010.09.016;
RA   Weitzel D.H., Chambers J., Haystead T.A.;
RT   "Phosphorylation-dependent control of ZIPK nuclear import is species
RT   specific.";
RL   Cell. Signal. 23:297-303(2011).
RN   [23]
RP   FUNCTION IN REGULATION OF AUTOPHAGY, AND INTERACTION WITH ULK1.
RX   PubMed=21169990; DOI=10.1038/emboj.2010.338;
RA   Tang H.W., Wang Y.B., Wang S.L., Wu M.H., Lin S.Y., Chen G.C.;
RT   "Atg1-mediated myosin II activation regulates autophagosome formation
RT   during starvation-induced autophagy.";
RL   EMBO J. 30:636-651(2011).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH NLK.
RX   PubMed=21454679; DOI=10.1074/jbc.M110.189829;
RA   Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R.,
RA   Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.;
RT   "Zipper-interacting protein kinase (ZIPK) modulates canonical
RT   Wnt/beta-catenin signaling through interaction with Nemo-like kinase
RT   and T-cell factor 4 (NLK/TCF4).";
RL   J. Biol. Chem. 286:19170-19177(2011).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH ATF4.
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [26]
RP   FUNCTION IN REORGANIZATION OF ACTIN CYTOSKELETON, AND INTERACTION WITH
RP   RHOD.
RX   PubMed=23454120; DOI=10.1016/j.bbrc.2013.02.046;
RA   Nehru V., Almeida F.N., Aspenstrom P.;
RT   "Interaction of RhoD and ZIP kinase modulates actin filament assembly
RT   and focal adhesion dynamics.";
RL   Biochem. Biophys. Res. Commun. 433:163-169(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-277.
RA   Kursula P., Vahokoski J., Wilmanns M.;
RT   "Crystal structure of human ZIP kinase.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 9-289 IN COMPLEX WITH
RP   PYRIDONE 6, ENZYME REGULATION, SUBUNIT, AND PHOSPHORYLATION AT SER-50
RP   AND THR-265.
RX   PubMed=18239682; DOI=10.1038/emboj.2008.8;
RA   Pike A.C., Rellos P., Niesen F.H., Turnbull A., Oliver A.W.,
RA   Parker S.A., Turk B.E., Pearl L.H., Knapp S.;
RT   "Activation segment dimerization: a mechanism for kinase
RT   autophosphorylation of non-consensus sites.";
RL   EMBO J. 27:704-714(2008).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-112; ASN-161 AND SER-216.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which is involved in the
CC       regulation of apoptosis, autophagy, transcription, translation and
CC       actin cytoskeleton reorganization. Involved in the regulation of
CC       smooth muscle contraction. Regulates both type I (caspase-
CC       dependent) apoptotic and type II (caspase-independent) autophagic
CC       cell deaths signal, depending on the cellular setting. Involved in
CC       regulation of starvation-induced autophagy. Regulates myosin
CC       phosphorylation in both smooth muscle and non-muscle cells. In
CC       smooth muscle, regulates myosin either directly by phosphorylating
CC       MYL12B and MYL9 or through inhibition of smooth muscle myosin
CC       phosphatase (SMPP1M) via phosphorylation of PPP1R12A; the
CC       inhibition of SMPP1M functions to enhance muscle responsiveness to
CC       Ca(2+) and promote a contractile state. Phosphorylates MYL12B in
CC       non-muscle cells leading to reorganization of actin cytoskeleton.
CC       Isoform 2 can phosphorylate myosin, PPP1R12A and MYL12B.
CC       Overexpression leads to condensation of actin stress fibers into
CC       thick bundles. Involved in actin filament focal adhesion dynamics.
CC       The function in both reorganization of actin cytoskeleton and
CC       focal adhesion dissolution is modulated by RhoD. Positively
CC       regulates canonical Wnt/beta-catenin signaling through interaction
CC       with NLK and TCF7L2. Phosphorylates RPL13A on 'Ser-77' upon
CC       interferon-gamma activation which is causing RPL13A release from
CC       the ribosome, RPL13A association with the GAIT complex and its
CC       subsequent involvement in transcript-selective translation
CC       inhibition. Enhances transcription from AR-responsive promoters in
CC       a hormone- and kinase-dependent manner. Involved in regulation of
CC       cell cycle progression and cell proliferation. May be a tumor
CC       suppressor. {ECO:0000269|PubMed:10356987,
CC       ECO:0000269|PubMed:11384979, ECO:0000269|PubMed:11781833,
CC       ECO:0000269|PubMed:12917339, ECO:0000269|PubMed:15096528,
CC       ECO:0000269|PubMed:15367680, ECO:0000269|PubMed:16219639,
CC       ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:17158456,
CC       ECO:0000269|PubMed:18084323, ECO:0000269|PubMed:18995835,
CC       ECO:0000269|PubMed:21169990, ECO:0000269|PubMed:21408167,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:21487036,
CC       ECO:0000269|PubMed:23454120}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10356987, ECO:0000269|PubMed:11384979,
CC       ECO:0000269|PubMed:11781833, ECO:0000269|PubMed:15096528,
CC       ECO:0000269|PubMed:17126281, ECO:0000269|PubMed:18995835}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10356987};
CC   -!- ENZYME REGULATION: A sequential activation is proposed:
CC       autophosphorylation at consensus sites is leading to dimerization
CC       of the catalytic domain stabilized by phosphorylation at Ser-50
CC       and activation segment exchange (producing an active confirmation
CC       of both kinase modules in trans) followed by phosphorylation at
CC       Thr-180 in the activation segment and at other regulatory sites
CC       (Probable). Phosphorylation at Thr-180, Thr-225 and Thr-265 is
CC       essential for activity. Oligomerization is required for full
CC       enzymatic activity. Inhibited by pyridone 6 (K00225), a potent,
CC       ATP-competitive inhibitor. {ECO:0000269|PubMed:15611134,
CC       ECO:0000269|PubMed:17158456, ECO:0000269|PubMed:18239682,
CC       ECO:0000303|PubMed:18239682}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12 uM for myosin (isoform 2) {ECO:0000269|PubMed:17126281};
CC         KM=6.2 uM for myosin (isoform 1) {ECO:0000269|PubMed:17126281};
CC         KM=73 uM for MYL12B (isoform 2) {ECO:0000269|PubMed:17126281};
CC         KM=10.4 uM for MYL12B (isoform 1) {ECO:0000269|PubMed:17126281};
CC         Vmax=248 nmol/min/mg enzyme toward myosin (isoform 2)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=120 nmol/min/mg enzyme toward myosin (isoform 1)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=1.3 umol/min/mg enzyme toward MYL12B (isoform 2)
CC         {ECO:0000269|PubMed:17126281};
CC         Vmax=271 nmol/min/mg enzyme toward MYL12B (isoform 1)
CC         {ECO:0000269|PubMed:17126281};
CC   -!- SUBUNIT: Homooligomer in its kinase-active form (homotrimers and
CC       homodimers are reported); monomeric in its kinase-inactive form.
CC       Homodimerization is required for activation segment
CC       autophosphorylation (Probable). Isoform 1 and isoform 2 interact
CC       with myosin and PPP1R12A; interaction of isoform 1 with PPP1R12A
CC       is inhibited by RhoA dominant negative form. Interacts with NLK,
CC       DAXX, STAT3, RHOD (GTP-bound form) and TCP10L. Interacts with
CC       PAWR; the interaction is reported conflictingly: according to
CC       PubMed:17953487 does not interact with PAWR. Interacts with ULK1;
CC       may be a substrate of ULK1. {ECO:0000269|PubMed:12917339,
CC       ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:15910542,
CC       ECO:0000269|PubMed:16219639, ECO:0000269|PubMed:17126281,
CC       ECO:0000269|PubMed:18239682, ECO:0000269|PubMed:21169990,
CC       ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:21454679,
CC       ECO:0000269|PubMed:23454120, ECO:0000303|PubMed:18239682}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-77293, EBI-77293;
CC       O14974:PPP1R12A; NbExp=5; IntAct=EBI-77293, EBI-351726;
CC       Q10728:Ppp1r12a (xeno); NbExp=2; IntAct=EBI-9691390, EBI-918263;
CC       Q8TDR4:TCP10L; NbExp=5; IntAct=EBI-77293, EBI-3923210;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15910542, ECO:0000269|PubMed:20854903}.
CC       Cytoplasm {ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17953487,
CC       ECO:0000269|PubMed:20854903}. Note=Predominantly localizes to the
CC       cytoplasm but can shuttle between the nucleus and cytoplasm;
CC       cytoplasmic localization is promoted by phosphorylation at Thr-299
CC       and involves Rho/Rock signaling. {ECO:0000269|PubMed:17953487,
CC       ECO:0000269|PubMed:20854903}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus
CC       {ECO:0000269|PubMed:17126281}. Cytoplasm
CC       {ECO:0000269|PubMed:17126281}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus
CC       {ECO:0000269|PubMed:17126281}. Cytoplasm
CC       {ECO:0000269|PubMed:17126281}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=ZIPK-L;
CC         IsoId=O43293-1; Sequence=Displayed;
CC       Name=2; Synonyms=ZIPK-S;
CC         IsoId=O43293-2; Sequence=VSP_042059, VSP_042060;
CC         Note=The internal splice site between exon 8 and the 3' UTR,
CC         which yields this truncated isoform, is non-canonical.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 1 and isoform 2 are
CC       expressed in the bladder smooth muscle.
CC       {ECO:0000269|PubMed:15292222, ECO:0000269|PubMed:17126281}.
CC   -!- PTM: The phosphorylation status is critical for kinase activity,
CC       oligomerization and intracellular localization. Phosphorylation at
CC       Thr-180, Thr-225 and Thr-265 is essential for activity. The
CC       phosphorylated form is localized in the cytoplasm promoted by
CC       phosphorylation at Thr-299; nuclear translocation or retention is
CC       maximal when it is not phosphorylated. Phosphorylation increases
CC       the trimeric form, and its dephosphorylation favors a kinase-
CC       inactive monomeric form. Both isoform 1 and isoform 2 can undergo
CC       autophosphorylation. {ECO:0000269|PubMed:15367680,
CC       ECO:0000269|PubMed:15611134, ECO:0000269|PubMed:17158456,
CC       ECO:0000269|PubMed:20854903}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. DAP kinase subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB007144; BAA24955.1; -; mRNA.
DR   EMBL; AB022341; BAA81746.1; -; mRNA.
DR   EMBL; AK074799; BAG52004.1; -; mRNA.
DR   EMBL; BC126430; AAI26431.1; -; mRNA.
DR   EMBL; BC126432; AAI26433.1; -; mRNA.
DR   EMBL; AB265224; BAF34614.1; -; mRNA.
DR   CCDS; CCDS12116.1; -. [O43293-1]
DR   RefSeq; NP_001339.1; NM_001348.2. [O43293-1]
DR   RefSeq; XP_005259565.1; XM_005259508.1. [O43293-1]
DR   UniGene; Hs.631844; -.
DR   PDB; 1YRP; X-ray; 3.10 A; A/B=1-277.
DR   PDB; 2J90; X-ray; 2.00 A; A/B=9-289.
DR   PDB; 3BHY; X-ray; 1.24 A; A=9-289.
DR   PDB; 3BQR; X-ray; 1.75 A; A=9-289.
DR   PDB; 5A6N; X-ray; 1.70 A; A/B=9-289.
DR   PDB; 5A6O; X-ray; 1.60 A; A/B=9-289.
DR   PDBsum; 1YRP; -.
DR   PDBsum; 2J90; -.
DR   PDBsum; 3BHY; -.
DR   PDBsum; 3BQR; -.
DR   PDBsum; 5A6N; -.
DR   PDBsum; 5A6O; -.
DR   ProteinModelPortal; O43293; -.
DR   SMR; O43293; -.
DR   BioGrid; 107983; 55.
DR   IntAct; O43293; 45.
DR   MINT; MINT-6505325; -.
DR   STRING; 9606.ENSP00000301264; -.
DR   BindingDB; O43293; -.
DR   ChEMBL; CHEMBL2468; -.
DR   GuidetoPHARMACOLOGY; 2004; -.
DR   iPTMnet; O43293; -.
DR   PhosphoSitePlus; O43293; -.
DR   BioMuta; DAPK3; -.
DR   EPD; O43293; -.
DR   MaxQB; O43293; -.
DR   PaxDb; O43293; -.
DR   PeptideAtlas; O43293; -.
DR   PRIDE; O43293; -.
DR   DNASU; 1613; -.
DR   Ensembl; ENST00000301264; ENSP00000301264; ENSG00000167657. [O43293-1]
DR   Ensembl; ENST00000545797; ENSP00000442973; ENSG00000167657. [O43293-1]
DR   GeneID; 1613; -.
DR   KEGG; hsa:1613; -.
DR   UCSC; uc002lzc.2; human. [O43293-1]
DR   CTD; 1613; -.
DR   DisGeNET; 1613; -.
DR   GeneCards; DAPK3; -.
DR   GeneCards; MIR637; -.
DR   HGNC; HGNC:2676; DAPK3.
DR   HPA; HPA028569; -.
DR   HPA; HPA064809; -.
DR   MIM; 603289; gene.
DR   neXtProt; NX_O43293; -.
DR   OpenTargets; ENSG00000167657; -.
DR   PharmGKB; PA27144; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; ENOG410XRMJ; LUCA.
DR   GeneTree; ENSGT00760000118877; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG101549; -.
DR   InParanoid; O43293; -.
DR   KO; K08803; -.
DR   OMA; SLEHPWI; -.
DR   OrthoDB; EOG091G0J2O; -.
DR   PhylomeDB; O43293; -.
DR   TreeFam; TF314166; -.
DR   Reactome; R-HSA-418889; Ligand-independent caspase activation via DCC.
DR   SABIO-RK; O43293; -.
DR   SignaLink; O43293; -.
DR   SIGNOR; O43293; -.
DR   ChiTaRS; DAPK3; human.
DR   EvolutionaryTrace; O43293; -.
DR   GeneWiki; DAPK3; -.
DR   GenomeRNAi; 1613; -.
DR   PRO; PR:O43293; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000167657; -.
DR   CleanEx; HS_DAPK3; -.
DR   ExpressionAtlas; O43293; baseline and differential.
DR   Genevisible; O43293; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0016605; C:PML body; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0008140; F:cAMP response element binding protein binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043522; F:leucine zipper domain binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0017048; F:Rho GTPase binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0071346; P:cellular response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0000910; P:cytokinesis; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:UniProtKB.
DR   GO; GO:0043519; P:regulation of myosin II filament organization; IEA:Ensembl.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR020636; Ca/CaM-dep_Ca-dep_prot_Kinase.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24347; PTHR24347; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Apoptosis; ATP-binding;
KW   Chromatin regulator; Complete proteome; Cytoplasm; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Translation regulation;
KW   Tumor suppressor.
FT   CHAIN         1    454       Death-associated protein kinase 3.
FT                                /FTId=PRO_0000085914.
FT   DOMAIN       13    275       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      19     27       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      161    204       Activation segment.
FT                                {ECO:0000250|UniProtKB:O96017}.
FT   REGION      427    441       Leucine-zipper.
FT                                {ECO:0000303|PubMed:9488481}.
FT   ACT_SITE    139    139       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      42     42       ATP. {ECO:0000305}.
FT   BINDING      94     94       Inhibitor. {ECO:0000269|PubMed:18239682}.
FT   BINDING      96     96       Inhibitor. {ECO:0000269|PubMed:18239682}.
FT   MOD_RES      50     50       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18239682}.
FT   MOD_RES     180    180       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15611134,
FT                                ECO:0000269|PubMed:17158456}.
FT   MOD_RES     225    225       Phosphothreonine.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MOD_RES     265    265       Phosphothreonine; by autocatalysis and
FT                                ROCK1. {ECO:0000269|PubMed:15611134,
FT                                ECO:0000269|PubMed:17158456,
FT                                ECO:0000269|PubMed:18239682}.
FT   MOD_RES     299    299       Phosphothreonine; by autocatalysis, DAPK1
FT                                and ROCK1. {ECO:0000269|PubMed:15367680,
FT                                ECO:0000269|PubMed:15611134,
FT                                ECO:0000269|PubMed:17158456,
FT                                ECO:0000269|PubMed:20854903}.
FT   MOD_RES     306    306       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MOD_RES     309    309       Phosphoserine; by DAPK1.
FT                                {ECO:0000269|PubMed:15367680}.
FT   MOD_RES     311    311       Phosphoserine; by autocatalysis and
FT                                DAPK1. {ECO:0000269|PubMed:15367680,
FT                                ECO:0000269|PubMed:15611134}.
FT   MOD_RES     312    312       Phosphoserine; by DAPK1.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:15367680}.
FT   MOD_RES     318    318       Phosphoserine; by DAPK1.
FT                                {ECO:0000269|PubMed:15367680}.
FT   MOD_RES     326    326       Phosphoserine; by DAPK1.
FT                                {ECO:0000269|PubMed:15367680}.
FT   VAR_SEQ     313    322       LPPNNSYADF -> ASPIVAPVDA (in isoform 2).
FT                                {ECO:0000303|PubMed:17126281}.
FT                                /FTId=VSP_042059.
FT   VAR_SEQ     323    454       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17126281}.
FT                                /FTId=VSP_042060.
FT   VARIANT     112    112       T -> M (in a colorectal adenocarcinoma
FT                                sample; somatic mutation; greatly reduces
FT                                kinase acivity, increases cell
FT                                proliferation and cell survival).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21487036}.
FT                                /FTId=VAR_040438.
FT   VARIANT     161    161       D -> N (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation; greatly reduces
FT                                kinase acivity, increases cell
FT                                proliferation and cell survival).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21487036}.
FT                                /FTId=VAR_040439.
FT   VARIANT     216    216       P -> S (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation;
FT                                greatly reduces kinase acivity, increases
FT                                cell proliferation, cell adhesion and
FT                                cell survival).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21487036}.
FT                                /FTId=VAR_040440.
FT   MUTAGEN      42     42       K->A: Loss of kinase activity at low
FT                                concentrations of ATP.
FT                                {ECO:0000269|PubMed:17158456}.
FT   MUTAGEN     161    161       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17158456}.
FT   MUTAGEN     180    180       T->A: Greatly reduced kinase activity.
FT                                {ECO:0000269|PubMed:21487036}.
FT   MUTAGEN     225    225       T->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:17158456}.
FT   MUTAGEN     265    265       T->A: Loss of phosphorylation by ROCK1,
FT                                catalytically inactive.
FT                                {ECO:0000269|PubMed:17158456}.
FT   MUTAGEN     294    295       RR->AA: Cytoplasmic localization.
FT                                {ECO:0000269|PubMed:20854903}.
FT   MUTAGEN     299    300       TT->AA: Predominantly nuclear
FT                                localization.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MUTAGEN     299    299       T->A: Loss of phosphorylation by ROCK1.
FT                                {ECO:0000269|PubMed:17158456}.
FT   MUTAGEN     299    299       T->D: Predominantly cytoplasmic
FT                                localization; phosphomimetic.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MUTAGEN     427    427       V->A: Predominantly nuclear localization;
FT                                when associated with A-434 and A-441.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MUTAGEN     434    434       V->A: Predominantly nuclear localization;
FT                                when associated with A-427 and A-441.
FT                                {ECO:0000269|PubMed:15611134}.
FT   MUTAGEN     441    441       L->A: Predominantly nuclear localization;
FT                                when associated with A-427 and A-434.
FT                                {ECO:0000269|PubMed:15611134}.
FT   HELIX         9     12       {ECO:0000244|PDB:3BHY}.
FT   STRAND       13     21       {ECO:0000244|PDB:3BHY}.
FT   STRAND       23     32       {ECO:0000244|PDB:3BHY}.
FT   TURN         33     35       {ECO:0000244|PDB:3BHY}.
FT   STRAND       38     46       {ECO:0000244|PDB:3BHY}.
FT   HELIX        49     51       {ECO:0000244|PDB:2J90}.
FT   STRAND       53     56       {ECO:0000244|PDB:3BHY}.
FT   HELIX        58     70       {ECO:0000244|PDB:3BHY}.
FT   STRAND       79     84       {ECO:0000244|PDB:3BHY}.
FT   STRAND       86     94       {ECO:0000244|PDB:3BHY}.
FT   HELIX       101    108       {ECO:0000244|PDB:3BHY}.
FT   HELIX       113    132       {ECO:0000244|PDB:3BHY}.
FT   HELIX       142    144       {ECO:0000244|PDB:3BHY}.
FT   STRAND      145    148       {ECO:0000244|PDB:3BHY}.
FT   STRAND      150    154       {ECO:0000244|PDB:3BHY}.
FT   STRAND      157    159       {ECO:0000244|PDB:3BHY}.
FT   HELIX       171    175       {ECO:0000244|PDB:5A6N}.
FT   HELIX       176    178       {ECO:0000244|PDB:5A6O}.
FT   HELIX       181    183       {ECO:0000244|PDB:3BHY}.
FT   HELIX       186    189       {ECO:0000244|PDB:3BHY}.
FT   HELIX       197    212       {ECO:0000244|PDB:3BHY}.
FT   HELIX       222    230       {ECO:0000244|PDB:3BHY}.
FT   HELIX       238    241       {ECO:0000244|PDB:3BHY}.
FT   HELIX       246    253       {ECO:0000244|PDB:3BHY}.
FT   HELIX       260    262       {ECO:0000244|PDB:3BHY}.
FT   HELIX       266    271       {ECO:0000244|PDB:3BHY}.
FT   HELIX       273    280       {ECO:0000244|PDB:3BHY}.
SQ   SEQUENCE   454 AA;  52536 MW;  56773008A6A61CF0 CRC64;
     MSTFRQEDVE DHYEMGEELG SGQFAIVRKC RQKGTGKEYA AKFIKKRRLS SSRRGVSREE
     IEREVNILRE IRHPNIITLH DIFENKTDVV LILELVSGGE LFDFLAEKES LTEDEATQFL
     KQILDGVHYL HSKRIAHFDL KPENIMLLDK NVPNPRIKLI DFGIAHKIEA GNEFKNIFGT
     PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGE TKQETLTNIS AVNYDFDEEY
     FSNTSELAKD FIRRLLVKDP KRRMTIAQSL EHSWIKAIRR RNVRGEDSGR KPERRRLKTT
     RLKEYTIKSH SSLPPNNSYA DFERFSKVLE EAAAAEEGLR ELQRSRRLCH EDVEALAAIY
     EEKEAWYREE SDSLGQDLRR LRQELLKTEA LKRQAQEEAK GALLGTSGLK RRFSRLENRY
     EALAKQVASE MRFVQDLVRA LEQEKLQGVE CGLR
//
